Showing results (31-40 of 172) with videos related to
Sort By:
Pageof 18
Hematology. American Society of Hematology. Education Program|November 25, 2004
The molecular basis of leukemiaD Gary Gilliland, Craig T Jordan, Carolyn A FelixBest Practice & Research. Clinical Haematology|June 20, 2006
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapyJason Gotlib, N C P Cross, D Gary GillilandSeminars in Oncology|June 4, 2004
Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndromeRichard M Stone, D Gary Gilliland, Amy D KlionBlood|May 5, 2005
Drug therapy for acute myeloid leukemiaMartin S Tallman, D Gary Gilliland, Jacob M RoweBlood|April 30, 2009
The leukemic stem cell niche: current concepts and therapeutic opportunitiesSteven W Lane, David T Scadden, D Gary GillilandNature Reviews. Cancer|August 28, 2007
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersRoss L Levine, Animesh Pardanani, Ayalew Tefferi, et al.Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
A progenitor cell origin of myeloid malignanciesHiroshi Haeno, Ross L Levine, D Gary Gilliland, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2005
Genetics of myeloid malignancies: pathogenetic and clinical implicationsStefan Fröhling, Claudia Scholl, D Gary Gilliland, et al.Nature Reviews. Genetics|May 9, 2022
Traversing industry and academia in biomedicine: the best of both worlds?D Gary Gilliland, Aviv Regev, Eric E Schadt, et al.Current Opinion in Hematology|December 17, 2003
The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemiaJan Cools, Elizabeth H Stover, Iwona Wlodarska, et al.Pageof 18